<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888263</url>
  </required_header>
  <id_info>
    <org_study_id>672/09</org_study_id>
    <nct_id>NCT01888263</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single
      dose, crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,
      crossover, oral bioequivalence study of Lamotrigine Extended Release tablets 200mg of Dr.
      Reddy's Laboratories Limited, India comparing with that of LAMICTAL XR(containing
      Lamotrigine) Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC in
      healthy, adult, human subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Blood samples were withdrawn at predose (0.00) and 1.00, 2.00, 3.00, 4.50, 6.00, 7.50, 9.00, 10.50, 12.00, 13.50, 15.00, 16.50, 18.00, 20.00, 22.00, 24.00, 26.00, 30.00, 36.00, 48.00, 72.00, 96.00, 120.00, 144.00 and 168.00 hours post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lamotrigine Extended Release Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAMICTAL XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg</description>
    <arm_group_label>Lamotrigine Extended Release Tablets</arm_group_label>
    <arm_group_label>LAMICTAL XR</arm_group_label>
    <other_name>LAMICTAL XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects were selected based on the following inclusion criteria:

          -  Provide written informed consent.

          -  Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)
             weighing at least 50 kg.

          -  Having a body mass index between 18.5 and 24.9 (both inclusive), calculated as weight
             in Kg/height in m 2.

          -  Must be of normal health as determined by medical history, physical examination and
             laboratory investigation performed within 28 days prior to the commencement of the
             study. (Laboratory values must be within normal limits or considered by the physician
             / investigator to be of no clinical significance).

          -  Female Subjects

               -  Of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

               -  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria The subjects were excluded based on the following criteria during
        screening and during the study:

          -  Incapable of understanding the informed consent.

          -  Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

          -  Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

          -  Oral temperature is below 95.0°F or above 98.6°F.

          -  Pulse rate below 50/min or above 100/min.

          -  History of hypersensitivity or idiosyncratic reaction to investigational drug product
             or any other related drugs or its ingredients.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          -  Consumption of grapefruit for the past ten days prior to the check-in, in each period.

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking during sample collection period.

          -  Habit of tobacco chewing.

          -  Habit of alcoholism and difficulty in abstaining from alcohol during the sample
             collection period.

          -  Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee,
             chocolates and cola drinks) during the sample collection period.

          -  Intake of over the counter (OTC) or prescribed medications and enzyme modifying
             medication or systemic medication for the last 30 days before dosing.

          -  Clinically significant abnormalities and / or with significant diseases.

          -  Confirmed positive in alcohol screening.

          -  Confirmed positive in urine cotinine test.

          -  Confirmed positive in selected drug of abuse.

          -  Participated in any other clinical investigation using experimental drug/donated blood
             in past 90 days before the date of start of study.

          -  Confirmed positive in urine pregnancy test. xx. Female detected to be pregnant, breast
             feeding or who is likely to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Yadav K, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Private Limited</name>
      <address>
        <city>Balanagar</city>
        <state>Hyderabad</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Lamotrigine Extended Release</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

